WW International (NASDAQ:WW), the global weight management company formerly known as Weight Watchers, released its fourth quarter and full-year 2025 financial results, showing stronger-than-expected earnings despite a year-over-year decline in total revenue.
The company’s shares surged more than 12% following the report, trading just shy of $24 on Monday morning.
For the fourth quarter, WW reported revenue of $162.8 million, exceeding analysts’ estimates of $149.8 million by 8.7%, though representing an 11.7% decline compared with the same period in 2024.
The company posted a loss per share of $0.58, significantly better than the estimated loss of $2.03 per share, while adjusted EBITDA reached $18.04 million, surpassing estimates of $12.11 million.
The company highlighted continued growth in its clinical subscription business, which generated $27 million in Q4 revenue, up 32% year-over-year, with a total of 130,000 clinical subscribers. Total end-of-period subscribers across all services were 2.8 million.
WW executives emphasized the ongoing transformation of the weight management industry, particularly the rise of GLP-1 medications, which the company is integrating into its broader digital and behavioral support programs.
CEO Tara Comonte noted that members participating in the company’s GLP-1 Success Program lost an average of 29% more body weight than those using medication alone.
“We view 2026 as an important inflection year, unlocking the potential for sustainable future growth. The year ahead will focus on continuing our transformation and positioning Weight Watchers as the premier global destination for weight health in the GLP-1 era,” Comonte said.
Looking ahead, WW provided full-year 2026 guidance of $620 million to $635 million in revenue and adjusted EBITDA of $105 million to $115 million, slightly below analyst expectations.
The company projects approximately 2.65 million total subscribers and 200,000 clinical subscribers by the end of the first quarter of 2026, reflecting targeted marketing efforts to support clinical growth and brand repositioning.